Skip to Content


Class: Androgens
ATC Class: A14AA
VA Class: HS100
Chemical Name: 17β-Hydroxy-17-αmethyl-2-oxa-5α-androstan-3-one
Molecular Formula: C19H30O3
CAS Number: 53-39-4

Medically reviewed by Last updated on Nov 17, 2020.


    Peliosis Hepatis
  • Peliosis hepatis, a condition in which the liver contains blood-filled cysts, reported with androgen therapy.1 4 30 31 34 May present with minimal hepatic dysfunction,1 4 34 or effects may not be apparent until complicated by life-threatening liver failure or rupture of the cysts resulting in intra-abdominal hemorrhage.1 4 5 7 31 34 (See Hepatic Effects under Cautions.)

  • Discontinuance of androgen therapy usually results in resolution of liver lesions.1 4 32 34

    Hepatic Adenoma and Carcinoma
  • Liver cell tumors reported with androgen therapy.1 4 5 7 30 31 34 Tumors are usually benign and androgen dependent; hepatocellular carcinoma, sometimes fatal, also reported.1 4 5 7 34

  • Liver cell tumors associated with androgens are more vascular than other hepatic tumors; hepatic effects may not be apparent until complicated by life-threatening intra-abdominal hemorrhage.1 4 5 34

  • Discontinuance of androgen therapy often but not always results in regression or cessation of progression of the tumor.1 4 5 34

    Lipid Abnormalities
  • May markedly alter serum lipoprotein concentrations; decreased HDL- and increased LDL-cholesterol reported with androgen therapy.1 4 30 31 34 Consider increased risk of cardiovascular disease (e.g., atherosclerosis and CAD).1 4 31 34 (See Lipid Abnormalities under Cautions.)


Synthetic androgenic anabolic steroid hormone.1 4

Uses for Oxandrolone

Catabolic and Wasting Disorders

Adjunct to conventional therapy to promote weight gain in individuals who experience weight loss following extensive surgery, chronic infections (e.g., HIV-associated wasting syndrome; designated an orphan drug by FDA for this use),3 or severe trauma (e.g., burns, spinal cord injury).1 5 17 19 22 32

Adjunct to conventional therapy for management of unexplained weight loss.1

Corticosteroid-induced Protein Catabolism

Adjunct to conventional therapy to offset protein catabolism (e.g., muscle wasting, muscle pain or weakness, delayed wound healing, atrophy of protein matrix of bone) associated with long-term corticosteroid therapy.1 4 20 21 33


Labeled for the symptomatic treatment of bone pain accompanying osteoporosis.1 4 23

Misuse, Abuse, and Dependence

Androgens have been misused and abused by athletes, bodybuilders, weight lifters, and others to enhance athletic performance or physique.6 7 8 9 10 32 193 194

Based on review of data, FDA concluded that misuse and abuse of androgens associated with serious adverse cardiovascular, hepatic, endocrine, and mental health effects.193 194 (See Misuse, Abuse, and Dependence under Cautions.)

Medical and sports experts (e.g., International Olympic Committee) consider such use to be inappropriate and unacceptable because of known adverse effects and potential long-term sequelae.9 Such misuse by athletes is contrary to rules and ethical principles of athletic competition.7 8 9 10

Manufacturer states that androgens have not been shown to enhance athletic performance.1

Evaluate serum testosterone concentrations if misuse or abuse of androgens suspected (e.g., patients experiencing serious adverse cardiovascular or psychiatric effects).194 Serum testosterone concentrations may be below or within the normal range in patients abusing synthetic derivatives of testosterone.135

Oxandrolone Dosage and Administration


  • Individualize dosage and duration of therapy carefully according to individual requirements, response, and tolerance.1 4 Use the minimum effective dosage; intended for intermittent use.1 4 22


Oral Administration

Administer orally 2–4 times daily in adults.1 4


Pediatric Patients

Catabolic and Wasting Disorders

≤0.1 mg/kg daily for 2–4 weeks.1 4 Repeat course of therapy intermittently as needed to maintain weight.1 4 32

Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response (i.e., slowing or cessation of weight loss).1 4 32 A longer period of treatment is necessary to regain lost weight, especially if ongoing catabolic stressors are present.32

Higher than recommended dosage of 0.1 mg/kg twice daily for 5 days to 12 months has been evaluated in pediatric patients with burns.1 4 5 16 17 18 32

Corticosteroid-induced Protein Catabolism

≤0.1 mg/kg daily.1 4 Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response.1 4 32 Repeat course of therapy intermittently as needed.1 4 32


Catabolic and Wasting Disorders

2.5–20 mg daily in 2–4 divided doses for 2–4 weeks.1 4 Repeat course of therapy intermittently as needed to maintain weight.1 4 32

Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response (i.e., slowing or cessation of weight loss).1 4 32 A longer period of treatment is necessary to regain lost weight, especially if ongoing catabolic stressors are present.32 Continuous administration for 3–4 months has been evaluated in patients with HIV-associated wasting syndrome.5 19

Corticosteroid-induced Protein Catabolism

2.5–20 mg daily in 2–4 divided doses.1 4 Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response.1 4 32 Repeat course of therapy intermittently as needed.1 4 32

Bone Pain

2.5–20 mg daily in 2–4 divided doses.1 4 Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response.1 4 Repeat course of therapy intermittently as needed.1 4

Special Populations

Geriatric Patients

5 mg twice daily for 2–4 weeks recommended.1 Repeat course of therapy intermittently as needed.1 (See Geriatric Use under Cautions.)

Cautions for Oxandrolone


  • Males with breast cancer or known or suspected prostate cancer.1 4

  • Women with hypercalcemia associated with metastatic breast cancer.1 4 (See Hypercalcemia under Cautions.)

  • Known or suspected pregnancy.1 4 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)

  • Nephrosis.1 4

  • Hypercalcemia.1 4 (See Hypercalcemia under Cautions.)



Fetal/Neonatal Morbidity and Mortality

May cause fetal harm; potential for virilization of fetus.1 4

Fetotoxicity, embryotoxicity, infertility, and virilization of female offspring demonstrated in animals.1 4

Hepatic Effects

Potentially serious and/or life-threatening adverse hepatic effects (e.g., peliosis hepatis, hepatic adenomas, hepatocellular carcinoma) associated with prolonged use of high dosages of androgens.5 6 7 9 10 22 (See Boxed Warning.)

If cholestatic hepatitis with jaundice occurs, or if liver function test results become abnormal during therapy, discontinue oxandrolone and investigate etiology of these disorders.1 4 Drug-induced jaundice usually is reversible after discontinuance of drug.1 4

Monitor liver function periodically.1 4 17 22


Possible hypercalcemia resulting from osteolysis in women with metastatic carcinoma of the breast.1 4 Monitor urine and serum calcium concentrations frequently during the course of androgen therapy in women with metastatic breast cancer.1 4 30

If hypercalcemia occurs, discontinue the drug.1 4 (See Contraindications under Cautions.)

Fluid Retention

Edema, with or without CHF, possible as a result of sodium and water retention and may be a serious complication in patients with preexisting cardiac, renal, or hepatic disease.1 4 30 (See Geriatric Use under Cautions.)

Misuse, Abuse, and Dependence

Serious adverse effects (e.g., increased aggression,6 7 8 10 13 22 antisocial behavior,6 7 manic episode,6 22 hostility,194 depression,9 changes in libido,6 7 8 9 10 22 increased risk of cardiovascular events,6 7 8 9 hepatotoxicity,6 7 8 9 10 testicular atrophy, sperm abnormalities135 193 194 ) associated with misuse and abuse of androgens (see Misuse, Abuse, and Dependence under Uses); oxandrolone preparations currently subject to control as schedule III (C-III) drugs.11 32

Manifestations of withdrawal (e.g., depressed mood, major depression, fatigue, cravings, restlessness, irritability, anorexia, insomnia, decreased libido, hypogonadotropic hypogonadism) may occur if androgens discontinued abruptly or dosage substantially reduced in physically dependent patients or in those taking supratherapeutic dosages of the drug; withdrawal symptoms may persist for weeks or months.135

General Precautions


Virilization, including baldness, clitoral enlargement, deepening of voice, hirsutism, and menstrual irregularities, may occur in females.1 4 5 6 9 13

Monitor women receiving oxandrolone therapy for signs of virilization.1 4 If virilization occurs, promptly discontinue therapy.1 4 Some changes may not be reversible (e.g., clitoral enlargement, voice changes) after discontinuance of the drug; concomitant use of estrogen with androgens does not prevent these effects.1 4 6 7 32

Hematologic Effects

Possible polycythemia, especially with high dosages of androgens.1 4 30 Perform periodic hemoglobin and hematocrit determinations in patients receiving high dosages of androgens.1 4 30

Anabolic steroids may suppress clotting factors II, V, VII, and X and prolong PT.1 4 (See Specific Drugs and Laboratory Tests under Interactions.)

Lipid Abnormalities

Androgens may increase LDL-cholesterol and decrease HDL-cholesterol concentrations; consider the increased risk for cardiovascular disease.1 4 5 6 7 10 12 13 19 22 32 Lipid concentrations return to baseline values approximately 1 month after discontinuance of androgen therapy.22

Use with caution in patients with cardiovascular disease or risk factors for cardiovascular disease.1 4 Determine serum lipid concentrations periodically; adjust therapy accordingly.1 4

Specific Populations


Category X.1 4 (See Fetal/Neonatal Morbidity and Mortality and also Contraindications under Cautions.)


Not known whether oxandrolone is distributed into milk.1 4 Discontinue nursing or the drug.1 4

Pediatric Use

May accelerate bone maturation without producing compensatory gain in linear growth, possibly resulting in compromised adult stature.1 4 10 The younger the child, the greater the risk of the drug compromising final mature stature.1 4

Use with extreme caution in children and only under the supervision of a specialist who is aware of the adverse effects of oxandrolone on bone maturation.1 4 Perform radiographic examination of the left hand and wrist every 6 months to determine rate of bone maturation and to assess the effect of treatment on epiphyseal centers.1 4

Geriatric Use

Possible increased risk of developing prostatic hypertrophy and prostate cancer during androgen therapy.1 4 30

Response in patients ≥65 years of age does not appear to differ from that in younger adults.1 Increased sensitivity to fluid retention and increases in hepatic transaminase values reported, particularly in geriatric women.1 Use lower dosage to minimize adverse effects.1 (See Geriatric Patients under Dosage and Administration.)

Common Adverse Effects

Elevated aminotransferases (ALT, AST),1 4 5 13 17 19 lipid abnormalities (e.g., decreased HDL cholesterol concentrations).1 4 5 13 19

Interactions for Oxandrolone

Specific Drugs and Laboratory Tests

Drug or Test



Anticoagulants, oral

May potentiate action of oral anticoagulants and decrease anticoagulant requirements1 4 22 24 26 32

Increases AUC and half-life of warfarin; minor bleeding reported;1 4 80-85% decrease in warfarin dosage (from a mean of 6.13 mg daily to a mean of 1.13 mg daily) were needed to maintain target INR of 1.5 in one study1 4 32

Monitor PT or INR when oxandrolone therapy is initiated or discontinued in patients receiving oral anticoagulants and adjust anticoagulant dosage as needed1 4 32

Initial anticoagulant dosage may be substantially lower in patients receiving oxandrolone32

Monitor for signs and symptoms of occult bleeding1 4

Antidiabetic agents, oral (sulfonylureas)

Possible inhibition of sulfonylurea metabolism1 4 32

Use concomitantly with care6

Corticotropin (ACTH) and corticosteroids

May exacerbate edema1 4

Consider possibility of interaction before use13

Tests for thyroid function

Possible decreased thyroxine-binding globulin concentrations, resulting in decreased total serum thyroxine (T4) concentrations and increased resin uptake of triiodothyronine (T3) and T41 4 16

Free thyroid hormone concentrations remain unchanged1 4

May decrease protein-bound iodine (PBI) concentrations and radioactive iodine uptake1 4

Oxandrolone Pharmacokinetics



Well absorbed after oral administration, with peak serum concentrations attained in approximately 1 hour.5 13


Plasma Protein Binding

95%.5 13



Partially metabolized via sulfation to 17-epioxandrolone; other metabolites also identified.5 13 14 25 27 28

Elimination Route

Excreted principally in urine as unchanged and unconjugated oxandrolone (28%).5 25 27


Biphasic; distribution half-life is 30 minutes and elimination half-life is approximately 10.4 hours in adults.1 5 25

Special Populations

In geriatric individuals, elimination half-life is 13.3 hours.1







  • Produces marked anabolic activity and relatively few androgenic effects.5 6 7 13 14 22

  • Produces retention of nitrogen,5 7 13 17 22 increases protein anabolism and amino acid utilization, and decreases urinary calcium concentrations.2 5 13 16 18 23

  • Increases lean body mass, body cell mass, and muscle strength.7 9 16 17 18 19 20 22

  • Increases bone mineral density and content.5 13 16 22

  • Inhibits protein catabolism induced by corticosteroids.5 6 8 17 22

  • Androgens stimulate production of erythrocytes, apparently by enhancing production of erythropoietin.22 (See Hematologic Effects under Cautions.)

  • Inhibits release of endogenous testosterone via feedback inhibition of pituitary luteinizing hormone (LH).1 4 7 8 10 19 22 32

  • Large doses of androgens may suppress spermatogenesis.1 4 6 7 8 9 22

Advice to Patients

  • Importance of advising patients of the potential for serious adverse effects associated with misuse and abuse of androgens.135

  • Risk of virilization in females.1 2 4 6 Advise female patients to contact their clinician if they notice hoarseness, acne, menstrual changes, baldness, genital changes, or growth of facial hair.1 2 4

  • Risk of priapism; importance of males informing clinicians if too frequent or persistent penile erections occur.1 4

  • Advise male patients to contact their clinician if they notice new or worsening acne.1 4

  • Importance of periodic assessments to determine rate of bone maturation in pediatric patients.1 4

  • Importance of informing clinician if nausea, vomiting, changes in skin color, or ankle swelling occurs.1 4

  • Risk of potential liver toxicity and/or lipid abnormalities (e.g., increased LDL-cholesterol concentrations and decreased HDL-cholesterol concentrations).1 4 Importance of regular laboratory monitoring of liver function and cholesterol concentrations.1 4

  • Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.1 4

  • Importance of informing clinician of existing or contemplated concomitant therapy, including prescription (e.g., warfarin, antidiabetic medications) and OTC drugs and herbal supplements, as well as any concomitant illnesses.1 4

  • Importance of informing patients of other important precautionary information.1 4 (See Cautions.)


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Oxandrolone is subject to control under the Federal Controlled Substances Act of 1970, as amended by the Anabolic Steroids Control Act of 1990 and 2004, as a schedule III (C-III) drug.11



Dosage Forms


Brand Names




2.5 mg

Oxandrolone Tablets (C-III; scored)

10 mg

Oxandrolone Tablets (C-III)

AHFS DI Essentials™. © Copyright 2021, Selected Revisions November 27, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.


1. Savient Pharmaceuticals. Oxandrin (oxandrolone) tablets prescribing information. East Brunswick, NJ; 2006 Jan.

2. AHFS consumer medication information. Oxandrolone. Bethesda, MD: American Society of Health-System Pharmacists; 2004 Oct 1. Available from website. Accessed 2008 Mar 7.

3. Food and Drug Administration. List of orphan designations and approvals. Rockville, MD; 2007 Oct 4. From FDA website. Accessed 2008 Mar 7.

4. Par Pharmaceutical Companies. Oxandrolone tablets prescribing information. Spring Valley, NY; 2007 Mar 3.

5. Orr R, Singh MF. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs. 2004; 64:725-50.

6. Kam PCA, Yarrow M. Anabolic steroid abuse: physiological and anaesthetic considerations. Anaesthesia. 2005; 60:685-92.

7. American College of Sports Medicine. Position stand on the use of anabolic-androgenic steroids in sports. Med Sci Sports Exerc. 1987; 19:534-9.

8. Committee on Sports Medicine and Fitness, American Academy of Pediatrics. Adolescents and anabolic steroids: a subject review. Pediatrics. 1997; 99:904-8.

9. Council on Scientific Affairs, American Medical Association. Medical and nonmedical uses of anabolic-androgenic steroids. JAMA. 1990; 264:2923-7.

10. Council on Scientific Affairs, American Medical Association. Drug abuse in athletes: anabolic steroids and human growth hormone. JAMA. 1988; 259:1703-5.

11. Drug Enforcement Administration (DEA), Department of Justice. Implementation of the Anabolic Steroid Control Act of 2004. Final rule. [21 CFR Part 1300 and 1308] Fed Regist. 2005; 70:74653-8.

12. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical practice guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update. Endocr Pract. 2002; 8:440-56.

13. Akyurek M, Dunn RM. Oxandrolone. Plast Reconstr Surg. 2006; 118:791-4.

14. Schänzer W. Metabolism of anabolic androgenic steroids. Clin Chem. 1996; 42:1001-20.

16. Przkora R, Jeschke MG, Barrow RE et al. Metabolic and hormonal changes in severely burned children receiving long-term oxandrolone treatment. Ann Surg. 2005; 242:384-91.

17. Jeschke MG, Finnerty CC, Suman OE et al. The effect of oxandrolone on the endocrinologic, inflammatory, and hypermetabolic reponses during the acute phase postburn. Ann Surg. 2007; 246:351-62.

18. Wolf SE, Thomas SJ, Dasu MR et al. Improved net protein balance, lean mass, and gene expression changes with oxandrolone treatment in the severely burned. Ann Surg. 2003; 237:801-11.

19. Grunfeld C, Kotler DP, Dobs A et al. Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. J Acquir Immune Defic Syndr. 2006; 41:304-14.

20. Kravetz JD, Lee C, Dieterich DT. Oxandrolone use in Crohn’s disease. Am J Gastroenterol. 1997; 92:2330-1. Letter

21. Dickerman RD, Joseph AM, Bennett MT. Corticosteroid-induced myopathy in spinal cord injury patients: a role for anticatabolic agents? Spinal Cord. 2006; 44:263-4. Letter

22. Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther. 2001; 23:1355-90.

23. Riggs BL, Jowsey J, Kelly PJ et al. Studies on pathogenesis and treatment in postmenopausal and senile osteoporosis. Clin Endocrinol Metab. 1973; 2:317-32.

24. Bristol-Myers Squibb. Coumadin (warfarin sodium) tablets crystalline and Coumadin (warfarin sodium) for injection prescribing information. Princeton, NJ; 2007 Aug.

25. Massé R, Bi H, Ayotte C et al. Studies on anabolic steroids II—Gas chromatographic/mass spectrometric characterization of oxandrolone urinary metabolites in man. Biomed Environ Mass Spectrom. 1989; 18:429-38.

26. Koller EA, Wei X, Johnson TE. Oxandrolone steroid use and impaired coagulation. Arch Intern Med. 2006; 166:125. Letter.

27. Bi H, Massé R. Studies on anabolic steroids—12. Epimerization and degradation of anabolic 17β-sulfate-17α-methyl steroids in human: qualitative and quantitative GC/MS analysis. J Steroid Biochem Molec Biol. 1992; 42:533-46.

28. Gonzalez FJ, Tukey RH. Drug metabolism. In: Brunton L, Lazo JS, Parker KL, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006:82.

29. August D, Teitelbaum D, Albina J et al. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. Section XI: Specific guidelines for disease—adults. JEPN. 2002; 26:61S-96SA.

30. ICN Pharmaceuticals. Android (methyltestosterone) capsules prescribing information. Costa Mesa, CA; 2001 Sep.

31. Upsher-Smith Laboratories. Androxy (fluoxymesterone) tablets prescribing information. Minneapolis, MN; 2006 May.

32. Savient Pharmaceuticals, East Brunswick, NJ: Personal communication

33. AHFS drug information 2008. McEvoy GK, ed. Corticosteroids general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2008:3088.

34. Alaven Pharmaceutical. Anadrol (oxymetholone) prescribing information. Marietta, GA; 2006 Dec.

135. Abbvie. AndroGel 1% (testosterone) topical gel prescribing information. North Chicago, IL; 2016 Oct.

193. Christou MA, Christou PA, Markozannes G et al. Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and Recreational Users: A Systematic Review and Meta-Analysis. Sports Med. 2017; 47:1869-83.

194. Food and Drug Administration. Testosterone and other anabolic androgenic steroids (AAS): FDA statement - risks associated with abuse and dependence. Silver Spring, MD; 2016 Oct 25. From the FDA website. Accessed 2017 Apr 7.